Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation by Wightman, Emma L. et al.
Effects of resveratrol alone or in combination with piperine on cerebral
blood flow parameters and cognitive performance in human subjects:
a randomised, double-blind, placebo-controlled, cross-over investigation
Emma L. Wightman1*, Jonathon L. Reay2, Crystal F. Haskell1, Gary Williamson3, Tristan P. Dew3
and David O. Kennedy1
1Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle upon Tyne NE1 8ST, UK
2School of Social Sciences and Law, Teesside University, Middlesbrough TS1 3BA, UK
3School of Food Science and Nutrition, University of Leeds, Leeds LS2 9JT, UK
(Submitted 26 April 2013 – Final revision received 23 December 2013 – Accepted 23 January 2014 – First published online 7 May 2014)
Abstract
Previous research has shown that resveratrol can increase cerebral blood flow (CBF) in the absence of improved cognitive performance in
healthy, young human subjects during the performance of cognitively demanding tasks. This lack of cognitive effects may be due to low
bioavailability and, in turn, reduced bioefficacy of resveratrol in vivo. Piperine can alter polyphenol pharmacokinetics, but previous studies
have not investigated whether this affects the efficacy of the target compound. Therefore, the objective of the present study was to ascertain
whether co-supplementation of piperine with resveratrol affects the bioavailability and efficacy of resveratrol with regard to cognition and
CBF. The present study utilised a randomised, double-blind, placebo-controlled, within-subjects design, where twenty-three adults were
given placebo, trans-resveratrol (250 mg) and trans-resveratrol with 20 mg piperine on separate days at least a week apart. After a
40 min rest/absorption period, the participants performed a selection of cognitive tasks and CBF was assessed throughout the period,
in the frontal cortex, using near-IR spectroscopy. The presence of resveratrol and its conjugates in the plasma was confirmed by liquid
chromatography–MS analysis carried out following the administration of the same doses in a separate cohort (n 6). The results indicated
that when co-supplemented, piperine and resveratrol significantly augmented CBF during task performance in comparison with placebo
and resveratrol alone. Cognitive function, mood and blood pressure were not affected. The plasma concentrations of resveratrol and its
metabolites were not significantly different between the treatments, which indicates that co-supplementation of piperine with resveratrol
enhances the bioefficacy of resveratrol with regard to CBF effects, but not cognitive performance, and does this without altering
bioavailability.
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Resveratrol (3,5,40-trihydroxystilbene) is a polyphenolic secondary
metabolite produced within plants in response to a range of
environmental stressors(1). Resveratrol ingestion has also been
shown to have protective effects in animals and human subjects.
Of direct relevance here is that these effects include the protection
of cognitive function/reversalof cognitivedeficits inanimalmodels
following supplementation(2), which may, in large part, be due to
the cerebral blood flow (CBF) effects exerted by resveratrol(3).
These CBF effects are likely to be mediated by the ability of resver-
atrol to modulate NO synthesis(4), with oral intervention shown
to enhance endothelium-dependent relaxation in rats(5,6) and
improve flow-mediated dilatation in overweight/obese human
subjects(7). An increase in blood-borne neural metabolic substrates
such as oxygen(8) and glucose(9) has been reported to enhance
aspects of cognitive performance in healthy, young human
subjects. Taken together, it could be hypothesised that an acute
increase in CBF, augmenting the delivery of metabolic substrates,
might also beneficially affect cognitive performance.
A recent study carried out in our laboratory has demon-
strated a dose-related increase in prefrontal cortex CBF
during the performance of cognitively demanding tasks in
healthy, young adults. This effect was consistent across all
time points for 500 mg of resveratrol, but failed to reach
significance for 250 mg. The increase in CBF did not facilitate
improved cognitive task performance(10). It was argued that
this might be due to the low bioavailability of resveratrol.
The pepper-derived alkaloid piperine has been observed
to be a potent enhancer of the bioavailability of numerous
compounds, including polyphenols, in vivo, for instance,
epigallocatechin-3-gallate in rodents(11), curcumin in rats
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and human subjects(12), and b-carotene following 14 d of
co-supplementation in human subjects(13). Co-supplementation
of piperine with resveratrol (10 mg/kg) has been reported to
induce 1544 % enhancement of maximum serum resveratrol
levels (compared with 100 mg/kg resveratrol alone) and
increase exposure (AUC) by 229 % in mice(14). Potential mech-
anisms for these phenomena include inhibition of enzymes
responsible for the metabolism of polyphenols(14–16),
enhancement of metabolism via thermogenic effects(13) and/
or competition for membrane efflux pumps in the body and
brain: phenomena observed when plant-derived compounds
are co-administered, e.g. polyphenols(17). However, these
studies did not investigate whether increased bioavailability
leads to increased bioefficacy of the target compound.
Therefore, the present randomised, double-blind, placebo-
controlled, cross-over study investigated the effects of
250 mg resveratrol when administered alone and when
co-supplemented with 20 mg piperine. The rationale for
using 250 mg resveratrol in the present study is based on
the previous ineffectiveness of this dose in modulating CBF
and the expectation that this will be augmented by the
actions of piperine. The aim was to ascertain whether piperine
is capable of enhancing the bioefficacy of resveratrol
with regard to CBF and cognitive performance in healthy
adults. Blood plasma concentrations of resveratrol were
measured to investigate whether bioavailability correlated
with bioefficacy.
Experimental methods
Participants (cerebral blood flow and cognitive
performance assessment)
A total of twenty-three healthy adults (four males and nineteen
females, mean age 21 years, range 19–34 years, SD 3·2 years,
all right handed) took part in all the three arms of the cross-
over study. The data collected from one participant were
excluded from the analysis due to data catchment errors.
All participants visited the laboratory after a 12 h overnight
fast and reported to meet the inclusion criteria, i.e. to be in
good health and free from social drug, alcohol, prescription
medication, and herbal extract/food supplement use, relevant
food allergies, intolerances and digestive problems. A fasted
state was considered to be most appropriate due to the
individual differences involved in breakfast consumption
and the unknowns involved in the absorption of resveratrol
together with food. Although food deprivation has been
reported to deleteriously affect cognitive function previously
in children(18,19), more recent research in athletes during
Ramadan has been more ambiguous(20) and a well-controlled
study of healthy, young adults has found no detrimental
effects of fasting on cognitive performance(21). All participants
were non-smokers and did not consume excessive amounts of
caffeine (.6 cups of coffee or equivalent/d). In addition, par-
ticipants who had suffered a head injury, neurological dis-
order or neurodevelopmental disorder were excluded from
participation, as were those who had uncorrected sight pro-
blems or were pregnant or seeking to become so.
Participants (bioavailability assessment)
In the bioavailability analysis, six healthy (mean BMI
24·2 kg/m2, range 21·7–27·2 kg/m2, SD 2·38 kg/m2) male adults
(mean age 25·8 years, range 23–29 years) took part. Inclusion/
exclusion criteria were as per the CBF and cognitive perfor-
mance aspect of the study.
The present study was conducted according to the
guidelines laid down in the Declaration of Helsinki, and all
procedures involving human subjects were approved by the
Department of Psychology ethics committee of Northumbria
University. Written informed consent was obtained from all
subjects. The present trial was registered at ClinicalTrials.gov
(study identifier NCT01331382).
Treatments
During the three study visits, the participants received three
single-dose treatments in an order dictated by random allo-
cation to a counterbalancing (Latin square) order. The three
treatments comprised two capsules, with each combination
delivering an inert placebo, 250 mg of trans-resveratrol or
250 mg of trans-resveratrol plus 20 mg of piperine. The
treatments were administered in identical size 0 vegetable cap-
sules, which were prepared by the lead researcher and coded
by a third party who had no further involvement in any aspect
of the study. No member of the investigational team was
aware of the contents of the capsules until a blind-data
review was completed.
Near-IR spectroscopy
Relative changes in the absorption of near-infrared light were
measured at a time resolution of 10 Hz using a twelve-channel
Oxymon system (Artinis Medical Systems B.V.). The system
emitted two nominal wavelengths of light (approximately
765 and 855 nm) with an emitter/optode separation distance
of 4 cm. The differential pathlength factor was adjusted
according to the age of the participant. Relative changes in
the concentrations of oxy-Hb, deoxy-Hb and total Hb were
calculated by means of a modified Beer–Lambert law(22)
using the proprietorial software. Given the extended
recording period and the investigational aims, a simple
two-emitter/optode pair configuration was used (i.e. two
channels). The emitter/optode pairs were positioned over
the left and right frontal cortices using a standard optode
holder headband, which separated the pairs from each other
by 4 cm. Therefore, each pair collected data from an area
of prefrontal cortex that included the areas corresponding
to the International 10–20 system Fp1 and Fp2 electroence-
phalogram positions. The near-IR spectroscopy (NIRS) data
output was time stamped at the start of each task segment
to ensure that the data corresponded to the relevant epoch
of task performance.
Cognitive tasks
To maximise the cerebral activity-induced modulation of
blood flow, a pilot study was initially carried out with a
E. L. Wightman et al.204
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separate cohort of fifteen participants (three males and twelve
females, mean age 21·6 years, all right handed) to ascertain the
most ‘mentally demanding’ and ‘difficult’ tasks from a battery
of eleven tasks (data not reported). The five tasks used in
the study were all subjectively rated as both the most
‘demanding’ and most ‘difficult’ and have all previously been
shown to activate the frontal cortex in functional MRI
studies(23–25). A computerised battery of cognitive tasks were
delivered using the Computerised Mental Performance Assess-
ment System software.
Serial subtractions. The serial subtraction task consisted of
2 min each of serial 7 s, 13 s and 17 s. The task has been
described in detail by Kennedy et al. (10).
Rapid visual information processing. The rapid visual
information processing (RVIP) task has been described in
detail by Kennedy et al.(10).
N-back task. The three-back version of the N-back task
was used in this paradigm, requiring the participants to indi-
cate whether the letter presented on screen was also present
three-letter back in the letter sequence. The participants
were required to respond by pressing the ‘yes’ or ‘no’
button on the response box, to each letter, as quickly as
they could. This task includes sufficient stimuli (letters) to
last for at least 2 min, although this is dependent on speed
(i.e. slower reaction times will result in a lengthier task) and
is scored for accuracy and reaction time.
Mood visual analogue scales. The participants were
required to rate how ‘relaxed’, ‘alert’, ‘jittery’, ‘tired’, ‘tense’
and ‘mentally fatigued’ they felt by placing a cross with the
mouse and cursor on a 100 mm on-screen line between the
descriptors ‘not at all’ and ‘extremely’. They were also
required to rate their ‘overall mood’ on a scale anchored by
‘very poor’ to ‘very good’ and their levels of ‘headache’
between ‘not at all’ and ‘extremely’. The visual analogue
scales were scored as a percentage along the line denoting
more of the relevant adjective.
Procedure (cerebral blood flow and cognitive performance
assessment)
Each participant was required to visit the laboratory on four
occasions. The first of these was an initial screening/training
visit during which the participants provided written informed
consent, were screened with regard to the study inclusion/
exclusion criteria, briefed with regard to compliance require-
ments and given training in completing the cognitive tasks.
This visit was followed within 14 d by the first of three
active study morning sessions.
On each of the three active study morning sessions, which
were conducted 2–14 d apart, the participants visited the lab-
oratory at 08.30 hours in a fasted state and provided confir-
mation of continued compliance with regard to the
inclusion/exclusion criteria. After a 5 min seated resting
period, a blood pressure reading was taken, after which the
NIRS headband was fitted. The participants then completed
a series of mood visual analogue scales and two repetitions
of baseline cognitive tasks in the following order: serial 7 s;
RVIP; serial 13 s; N-back; serial 17 s. The participants then
rested for 10 min and a second blood pressure reading was
taken. Treatment was then administered, after which the par-
ticipants sat quietly, watching one of a selection of non-arous-
ing DVD for a 40 min ‘absorption’ period. Following this, a
third blood pressure reading was taken, after which the par-
ticipants completed four repetitions of the aforementioned
tasks in the same order and duration. After the completion
of the post-dose tasks, the same mood visual analogue
scales were presented and the fourth and final blood pressure
readings were taken. NIRS data were captured throughout the
5 
m
in
 r
es
t
B
P
B
P
B
P
B
P
0
Treatment
NIRS recording
40 45 55 65 75 85 95 100
M
o
o
d
 V
A
S
M
o
o
d
 V
A
S
7
s,
 R
V
IP
 , 
13
s,
 N
-b
ac
k,
 1
7
s 
7
s,
 R
V
IP
 , 
13
s,
 N
-b
ac
k,
 1
7
s 
7
s,
 R
V
IP
 , 
13
s,
 N
-b
ac
k,
 1
7
s 
7
s,
 R
V
IP
 , 
13
s,
 N
-b
ac
k,
 1
7
s 
7
s,
 R
V
IP
 , 
13
s,
 N
-b
ac
k,
 1
7
s 
7
s,
 R
V
IP
 , 
13
s,
 N
-b
ac
k,
 1
7
s 
Fig. 1. Timeline and running order of the test sessions. Upon arrival to the laboratory, the participants rested for 5 min before the first blood pressure (BP) reading
was taken. The near-IR spectroscopy (NIRS) headband was then fitted. Mood visual analogue scales (VAS) and two repetitions of baseline cognitive tasks were
completed, followed by a 10 min rest period. The second blood pressure reading was then taken and treatment was administered. After a 40 min absorption
period, the third blood pressure reading was taken. Later, four repetitions of the cognitively demanding tasks were completed, followed by mood VAS ratings and
the fourth and final blood pressure readings. RVIP, rapid visual information processing.
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sessions. The timeline and running order of the test sessions
are shown in Fig. 1.
Procedure (bioavailability assessment)
On each study morning, the participants visited the laboratory
at 08.30 hours. Venous blood samples were collected using
4·7 ml monovettes (containing lithium heparin) before the
administration of the day’s treatment and then 45, 90 and
120 min after the administration of treatment. The samples
were centrifuged at 2500 rpm for 15 min at 208C to obtain
plasma, which was then stored at 2808C until analysis.
Preparation of samples
Samples were handled in low-light conditions to reduce
the scope for isomerisation. Plasma samples were defrosted
at room temperature immediately before extraction, vortexed
and then sonicated for 5 min. A 200ml aliquot was mixed with
900ml of HPLC-grade ethanol plus 0·1 % formic acid (v/v),
along with 100ml of naringenin internal standard (IS1; Extra-
synthese) in ethanol (500 ng/ml). The samples were vortexed,
sonicated and then separated via micro-centrifugation at
17 000 g for 10 min. The supernatant was removed and
placed in an amber 1·5 ml centrifuge tube (Eppendorf). The
pellet was re-extracted with 1·2 ml of 83 % aqueous ethanol
(v/v) following the same protocol. Both extracts were evapor-
ated to dryness under vacuum using a centrifugal evaporator
(EZ2þ ; Genevac) and frozen at 2208C. On the day of anal-
ysis, a 70ml portion of ethanol was added to the secondary
extract, which was vortexed and sonicated. A 50ml aliquot
of this solution was then added to the primary extract,
which following vortexing and sonication was mixed with
50ml taxifolin (IS2 at 2mg/ml; Extrasynthese) in 0·2 % ascorbic
acid solution. This solution was vortexed and separated by
centrifugation, and the supernatant was placed in an amber
vial and analysed via liquid chromatography–MS. Extractions
were made in duplicate for each time point. To test the
extraction efficiency of this method, blank plasma was
spiked with standards at 50 nM, 500 nM, 5mM and 10mM
concentrations. Across this range, the average extraction effi-
ciencies for trans-resveratrol (Cayman Chemicals), resveratrol
3-O-sulphate, resveratrol 40-O-glucuronide and resveratrol
3-O-glucuronide (Bertin Pharma) were 74, 72, 52 and 55 %,
respectively. IS1 and IS2 were extracted consistently at 82
and 100 %, respectively.
Liquid chromatography–MS analysis
Liquid chromatography–MS analysis was conducted using
a Shimadzu LC2010CHT HPLC system, consisting of an inte-
grated quaternary pump, a degasser, a chilled autosampler
(88C) and a column oven (308C), connected to an LCMS2020
single quadrupole mass spectrometer. A 10ml sample aliquot
was separated on an XDB–C18 1·8mm, 4·6 £ 50 mm column
(Agilent), running a binary gradient of liquid chromato-
graphy–MS-grade water v. acetonitrile, both containing 0·1 %
formic acid (v/v), running at 0·5 ml/min. The gradient started
at 5 % acetonitrile and moved to 10 % at 5 min, 40 % at
20 min and 90 % at 25 min. Following 4 min of washing, the
column returned to running 5 % acetonitrile at 30 min and
was re-equilibrated over 3 min. The MS analysis was run
with an interface temperature set to 3508C, using nebuliser
and drying gas flow rates of 1·5 and 15 litres/min, respectively.
The analysis was carried out in a negative single-ion
monitoring mode, following m/z of 403 (glucuronides), 307
(sulphates), 271 (naringenin IS1), 303 (taxifolin IS2) and 227
(aglycone resveratrol). A persistent formate adduct of agly-
cone resveratrol (m/z 273) was also followed as a qualifying
ion. The limit of quantification was 16 nM for glucuronides,
22 nM for sulphates, and 145 and 290 nM for cis- and trans-
aglycone resveratrol, respectively. Peak areas were normalised
to that of IS2 for quantification, while IS1 was used to judge
individual sample extraction. The retention times of cis-
isomer resveratrol conjugates were identified by subjecting
commercially available trans-isomers (10mg/ml in 50 % aqu-
eous ethanol, plus 0·1 % ascorbic acid and 0·05 % formic
acid) to ultraviolet light (254 nm) for 4 h. Cis-isomer resveratrol
conjugates were quantified as trans-isomer equivalents and
then summed with the corresponding trans-isomers.
Statistical analyses
The analyses of plasma data were carried out with SPSS 16.0
for Windows (SPSS, Inc.) using within-subjects ANOVA
(treatment £ time) for each metabolite and paired-samples
t tests to compare AUC, Cmax and Tmax, between the two treat-
ments, for each metabolite.
NIRS data were analysed with Minitab 16 for Windows
(Minitab, Inc.). For each variable (oxy-Hb, deoxy-Hb and total
Hb), data were converted to ‘change from baseline’ (calculated
from a 10 min pre-treatment resting period) and averaged
across 2 min epochs during the 40 min ‘rest/absorption’ and
40 min cognitive task performance periods. The analysis was
based on an average of the two NIRS channels to give a measure
of cerebral haemodynamics across the prefrontal cortex as a
whole, in line with the method of Kennedy et al.(10).
The primary analysis of the averaged NIRS data was
conducted using within-subjects ANOVA (treatment £ 2 min
epoch) with a priori planned comparisons of data from each
epoch being made between placebo and each of the resveratrol
treatment groups (250 mg resveratrol and 250 mg resveratrol
with 20 mg piperine) using t tests calculated with the mean
squares error from the ANOVA(26). To protect against the possi-
bility of type 1 errors, planned comparisons are only reported if
they evinced a consistent pattern of significant effects across the
analysis period.
Task performance data (also analysed with SPSS 16.0) were
analysed as change from pre-dose baseline for each individual
task (serial 7 s, RVIP, serial 13 s, 3-back and serial 17 s) using
within-subjects ANOVA (treatment £ repetition), with planned
comparisons for data from each repetition being made as
described above.
A power calculation conducted using G* Power(27)
suggested that a sample size of twenty-four would be
adequate to have greater than an 80 % chance of detecting
E. L. Wightman et al.206
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the medium effect sizes demonstrated in previous research
assessing the effect of resveratrol on NIRS parameters(10).
Results
Near-IR spectroscopy parameters
Total Hb. The ANOVA of total Hb data revealed that
there was a significant interaction between the post-dose
epoch and treatment (P,0·01). Planned comparisons revealed
that, compared with placebo, treatment with 250 mg
resveratrol failed to elicit any modulation of total Hb levels.
However, following treatment with 250 mg resveratrol
combined with 20 mg piperine, although there were no
significant effects during the absorption period, total Hb
levels were significantly increased for all task performance
epochs (apart from 45, 51 and 79 min). Time points 41, 49
and 61 were all significant at the 0·05 level and the remainder
at the 0·01 level.
Oxygenated Hb (oxy-Hb). The ANOVA of oxy-Hb data
revealed that there was a significant interaction between the
post-dose epoch and treatment (P,0·05). The pattern was
similar to that observed for total Hb, with no modulation
being observed following treatment with 250 mg resveratrol,
but with significantly increased oxy-Hb levels being observed
following treatment with 250 mg resveratrol combined with
20 mg piperine (all epochs, P,0·01; epochs 45, 49 and 51,
P,0·05; and epoch 79, P¼NS).
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Fig. 2. Haemodynamic effects of 250 mg of trans-resveratrol alone and when co-supplemented with 20 mg of piperine in healthy, young human subjects. Changes
in the concentrations of (a) total Hb and (b) deoxygenated Hb (deoxy-Hb) during a 40 min absorption period and subsequent 40 min of cognitive task performance
following the administration of placebo (W), 250 mg trans-resveratrol (X) and 250 mg trans-resveratrol with 20 mg piperine (P). The study followed a cross-over
design (n 23 per condition). Data were averaged across 2 min epochs. A priori planned comparisons between data from each resveratrol group and those from
the placebo group for each epoch were made using t tests by incorporating mean squares error from an initial ANOVA. Values are means, with their standard
errors represented by vertical bars. Mean value was significantly different from that of the placebo group: *P,0·05, **P,0·01.
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Table 1. Effects of resveratrol on cognitive performance
(Mean values with their standard errors; n 23)
Task battery repetition
Baseline 1 2 3 4 ANOVA
Measures Treatment condition Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Effect F P
7 s Correct (n) 250 mg resveratrol 28·85 2·75 1·20 1·02 1·98 0·94 1·54 0·83 0·80 1·16 T 0·252 0·778
250 mg resveratrol with 20 mg
piperine
28·83 2·59 1·52 0·85 20·04 0·94 0·39 1·25 0·57 1·13 R 0·487 0·692
Placebo 28·85 2·04 1·94 1·12 0·89 1·11 0·11 1·43 0·98 1·29 T £ R 0·675 0·606
7 s Incorrect (n) 250 mg resveratrol 1·87 0·30 0·35 0·51 20·26 0·37 0·35 0·38 0·70 0·55 T 0·517 0·600
250 mg resveratrol with 20 mg
piperine
1·67 0·23 0·11 0·39 0·67 0·38 1·33 0·52 1·07 0·49 R 2·09 0·110
Placebo 1·91 0·26 0·30 0·52 0·30 0·47 0·78 0·60 0·13 0·46 T £ R 1·02 0·416
13 s Correct (n) 250 mg resveratrol 22·22 2·25 0·70 0·88 20·78 0·90 0·22 0·87 21·17 0·98 T 1·68 0·199
250 mg resveratrol with 20 mg
piperine
22·46 2·17 1·33 0·75 21·15 1·26 20·11 1·25 1·07 0·87 R 3·17 0·030*
Placebo 21·83 1·60 3·26 0·83 0·78 1·41 1·17 1·20 1·09 1·03 T £ R 0·644 0·695
13 s Incorrect (n) 250 mg resveratrol 2·04 0·23 0·13 0·40 2·04 1·00 0·65 0·51 1·17 0·47 T 0·969 0·388
250 mg resveratrol with 20 mg
piperine
1·89 0·36 0·11 0·44 1·59 0·94 1·59 0·63 0·76 0·73 R 7·08 ,0·001**
Placebo 2·39 0·36 21·09 0·33 0·96 0·84 0·78 0·53 0·44 0·58 T £ R 0·445 0·765
17 s Correct (n) 250 mg resveratrol 17·22 1·68 1·39 0·71 1·48 0·81 2·35 0·75 1·09 1·13 T 0·405 0·670
250 mg resveratrol with 20 mg
piperine
17·78 1·61 0·39 0·63 0·44 0·86 0·87 0·90 2·13 0·76 R 0·502 0·638
Placebo 16·80 1·29 1·72 0·62 1·37 0·68 1·15 0·95 1·89 0·59 T £ R 1·07 0·383
17 s Incorrect (n) 250 mg resveratrol 2·28 0·28 0·15 0·41 0·02 0·47 0·24 0·52 1·54 1·09 T 0·719 0·493
250 mg resveratrol with 20 mg
piperine
2·17 0·29 0·30 0·42 0·30 0·50 0·57 0·42 0·52 0·37 R 1·41 0·254
Placebo 2·57 0·27 20·30 0·37 20·44 0·45 0·44 0·67 20·04 0·36 T £ R 0·791 0·578
N-back accuracy (%) 250 mg resveratrol 93·38 1·17 20·34 0·97 21·02 1·05 20·92 1·08 20·05 1·00 T 0·617 0·544
250 mg resveratrol with 20 mg
piperine
94·40 0·91 22·03 1·02 21·84 1·09 20·29 0·89 21·45 1·27 R 0·274 0·844
Placebo 94·40 0·74 21·26 1·08 21·55 0·92 22·61 1·13 01·45 0·93 T £ R 0·678 0·599
N-back reaction time
(ms)
250 mg resveratrol 1540·45 145·80 2291·04 48·75 2345·87 53·98 2312·95 52·58 2398·24 58·12 T 1·28 0·288
250 mg resveratrol with 20 mg
piperine
1476·26 189·03 2243·72 67·01 2287·30 77·69 2375·74 94·44 2292·16 70·96 R 3·93 0·012*
Placebo 1475·04 161·35 2194·12 34·69 2149·39 70·65 2264·79 81·89 2271·44 57·14 T £ R 1·12 0·347
RVIP correct (%) 250 mg resveratrol 71·06 3·76 0·41 2·98 24·48 2·44 27·47 3·73 27·76 2·58 T 1·17 0·321
250 mg resveratrol with 20 mg
piperine
65·81 4·00 3·76 2·32 1·31 3·39 24·36 3·39 21·68 3·51 R 7·58 ,0·001**
Placebo 69·16 3·90 1·50 2·25 27·38 3·65 27·47 2·51 26·66 3·40 T £ R 0·489 0·816
T, treatment; R, repetition; RVIP, rapid visual information processing.
There was a significant main effect for R: *P,0·05, **P,0·01.
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Deoxygenated Hb (deoxy-Hb). The ANOVA of deoxy-Hb
data revealed that there was no significant main effect or
interaction between time and treatment. Planned compari-
sons, however, demonstrated a consistent pattern of signifi-
cant effects, which began to emerge during the end of the
absorption phase and continued throughout the post-dose
task period. After treatment with 250 mg resveratrol combined
with 20 mg piperine, deoxy-Hb levels were significantly
increased in comparison with those observed after placebo
administration (absorption period: epochs 27, 29, 33, 35 and
37, P,0·05 and epoch 39, P,0·01; post-dose task period: all
epochs, P,0·01 and epoch 77, P,0·05).
The mean data (with their standard errors) and the results
of the planned comparisons for total Hb and deoxy-Hb are
shown in Fig. 2.
Cognitive task performance and mood
There were no significant treatment-related differences in any
cognitive or mood measures. The raw baseline task scores and
mood ratings and changes from baseline mean task scores
and mood ratings are given in Tables 1 and 2, respectively.
Blood pressure
No significant treatment-related differences were observed in
pulse rate and diastolic or systolic blood pressure. The raw
baseline blood pressure readings and changes from baseline
post-dose blood pressure readings are given in Table 3.
Bioavailability
No resveratrol (in any form) was found in baseline samples,
indicating that none of the participants consumed resveratrol
before the start of the study. Following oral intervention
with 250 mg of resveratrol, plasma concentrations of total
resveratrol metabolites ranged from 2 to 18·2mM, varying
between the participants and treatments. However, no agly-
cone trans- or cis-resveratrol was quantifiable in plasma.
Resveratrol 3-O-sulphate was the predominant metabolite in
all participants, contributing 59–81 % of total metabolites.
The 40-O-glucuronide and 3-O-glucuronide forms made
roughly equal contributions to the remaining metabolites in
circulation. Cmax was typically achieved at 90 min. Resveratrol
conjugates were present in plasma as both trans-isomers
and cis-isomers, varying between the participants. The aver-
age Cmax trans:cis ratios for resveratrol 3-O-sulphate and
resveratrol 3-O-glucuronide following the consumption of
all trans-resveratrol were 4·7 (SEM 5·6) (range 1·2–15·9) and
5·1 (SEM 5·6) (range 0·94–18·8), respectively. Cis-resveratrol
40-O-glucuronide was found in some, but not in all subjects.
Extraction efficiency tests did not indicate significant induction
of isomerisation during sample handling, suggesting that this
conversion occurs in vivo.
Although the average concentrations of resveratrol 3-O-sul-
phate, 40-O-glucuronide and 3-O-glucuronide at Cmax appeared
to be lower following the co-supplementation of resveratrol
with piperine compared with those following supplementation
of resveratrol alone, there was no significant difference
between the treatments. Similarly, there was no significant
Table 2. Effects of 250 mg resveratrol alone and when co-supplemented with 20 mg piperine on mood in healthy, young human subjects
(Mean values with their standard errors; n 23)
Baseline Post-dose ANOVA
Measures Treatment condition Mean SEM Mean SEM Effect F P
Alert 250 mg resveratrol 50·83 3·79 26·65 5·44 T 0·767 0·470
250 mg resveratrol with 20 mg piperine 49·13 3·78 4·43 4·07 R 0·359 0·555
Placebo 51·57 4·08 24·87 4·68 T £ R 3·28 0·047*
Jittery 250 mg resveratrol 16·83 2·91 19·78 5·40 T 0·532 0·591
250 mg resveratrol with 20 mg piperine 18·61 3·33 20·48 4·95 R 25·79 ,0·001**
Placebo 15·39 2·54 20·87 4·73 T £ R 0·022 0·979
Mental fatigue 250 mg resveratrol 28·96 4·69 35·65 6·18 T 0·839 0·439
250 mg resveratrol with 20 mg piperine 27·48 4·86 32·48 5·93 R 45·47 ,0·001**
Placebo 26·22 4·10 33·74 6·11 T £ R 0·147 0·864
Overall mood 250 mg resveratrol 62·87 3·46 216·13 4·48 T 2·66 0·081 t
250 mg resveratrol with 20 mg piperine 64·48 3·04 212·78 3·60 R 25·87 ,0·001**
Placebo 67·35 2·71 213·74 2·97 T £ R 0·321 0·727
Relaxed 250 mg resveratrol 62·91 2·67 224·52 5·62 T 0·566 0·572
250 mg resveratrol with 20 mg piperine 60·35 3·29 214·13 6·00 R 20·70 ,0·001**
Placebo 62·52 1·98 220·61 4·44 T £ R 1·79 0·179
Tense 250 mg resveratrol 25·48 3·29 25·74 6·35 T 2·32 0·110
250 mg resveratrol with 20 mg piperine 23·87 3·28 26·35 6·40 R 26·08 ,0·001**
Placebo 19·83 3·02 25·30 5·37 T £ R 0·016 0·984
Tired 250 mg resveratrol 47·09 4·51 14·57 5·33 T 0·405 0·669
250 mg resveratrol with 20 mg piperine 50·74 5·05 4·04 3·92 R 5·96 0·023*
Placebo 45·57 4·42 11·52 6·39 T £ R 1·72 0·191
T, treatment; R, repetition; t, trend.
There were significant main effects for R and the T £ R interaction: *P,0·05, **P,0·01.
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difference in the values of area under the curve, and there was
no significant change in Tmax between the treatments.
The mean plasma concentrations of trans-resveratrol 3-O-
sulphate and combined 40-O-glucuronide and 3-O-glucuronide
metabolites at pre-treatment and at 45, 90 and 120 min post-
dose time points, for both treatments, are shown in Fig. 3.
Discussion
The present study demonstrates that the well-established
bioenhancer piperine can increase the bioefficacy of the
polyphenol resveratrol when co-supplemented in healthy
human subjects. Whereas 250 mg of orally administered
trans-resveratrol had no significant effects on overall CBF
(total Hb) during the performance of cognitively demanding
tasks, co-administration of the same dose of resveratrol with
20 mg piperine resulted in significantly increased CBF for the
duration of the 40 min post-dose task period. The findings
with regard to the supplementation of resveratrol alone in
this respect are broadly in line with the dose–response pattern
of CBF observed following resveratrol administration in a
previous study, in which a dose of 250 mg was largely
ineffective(10). Despite this piperine-mediated enhancement
of the CBF effects of resveratrol, there were no significant
treatment-related differences in the performance of the cog-
nitive tasks, blood pressure/heart rate or participants’ ratings
of mood for either active treatment.
The pattern of haemodynamic effects of resveratrol
observed in the present study, when supplemented with
piperine, is exactly in line with that in the aforementioned
previous resveratrol intervention study following the adminis-
tration of a 500 mg dose(10). This pattern is observed as
significantly higher levels of total Hb and oxy-Hb, alongside
deoxy-Hb, during the post-dose cognitive task period and
represents increased CBF and oxygen utilisation, respectively.
This haemodynamic response is dissimilar to that observed
during cognitive task performance alone. Here, total Hb and
oxy-Hb levels typically rise alongside a concomitant decline
in deoxy-Hb levels(28), with this phenomenon being predi-
cated based on the fact that neural activation instigates an
increase in CBF that is greater than the metabolic rate of
oxygen extraction/utilisation. As such, deoxy-Hb levels can
be observed to decrease during cognitive performance(29).
The different deoxy-Hb response observed following resve-
ratrol treatment is probably predicated based on indirect
effects on mitochondrial phosphorylation. In support of this,
Lagouge et al.(30) reported that in mice supplemented with
400 mg/kg/d resveratrol, for 15 weeks, significantly increased
mitochondrial structures and enzymatic activity. This resulted
in a significant increase in VO2 and VO2 max rates and was
observed to increase running time and tolerance to cold. In
terms of mechanisms, resveratrol can interact with the sirtuin
(‘silent information regulator’; SIRT) system, a class of proteins
involved in multifarious biological processes that has received
a great amount of attention over the past decade in relation to
life extension(31). Of importance here is that SIRT is implicated
in the deacetylation of PPARg co-activator 1-a (PGC-1a), a
gene that controls mitochondrial biogenesis and function(32),T
a
b
le
3
.
E
ff
e
c
ts
o
f
2
5
0
m
g
re
s
v
e
ra
tr
o
l
a
lo
n
e
a
n
d
w
h
e
n
c
o
-s
u
p
p
le
m
e
n
te
d
w
it
h
2
0
m
g
p
ip
e
ri
n
e
o
n
b
lo
o
d
p
re
s
s
u
re
in
h
e
a
lt
h
y
,
y
o
u
n
g
h
u
m
a
n
s
u
b
je
c
ts
(M
e
a
n
v
a
lu
e
s
w
it
h
th
e
ir
s
ta
n
d
a
rd
e
rr
o
rs
)
T
a
s
k
b
a
tt
e
ry
re
p
e
ti
ti
o
n
B
a
s
e
lin
e
†
P
D
1
†
P
D
2
†
A
N
O
V
A
M
e
a
s
u
re
s
T
re
a
tm
e
n
t
c
o
n
d
it
io
n
M
e
a
n
S
E
M
M
e
a
n
S
E
M
M
e
a
n
S
E
M
E
ff
e
c
t
F
P
S
y
s
to
lic
b
lo
o
d
p
re
s
s
u
re
(m
m
H
g
)
2
5
0
m
g
re
s
v
e
ra
tr
o
l
1
1
2
1
·9
8
2
·3
5
1
·7
7
4
·8
7
1
·2
1
T
r
0
·6
2
1
0
·5
4
2
2
5
0
m
g
re
s
v
e
ra
tr
o
l
w
it
h
2
0
m
g
p
ip
e
ri
n
e
1
1
4
·1
7
1
·9
8
1
·3
9
1
·2
6
4
·9
0
1
·7
2
T
i
9
·6
1
0
·0
0
5
**
P
la
c
e
b
o
1
1
3
·2
2
2
·3
1
2
0
·0
4
1
·7
8
3
·3
9
2
·1
3
T
r
£
T
i
0
·0
8
9
0
·9
1
5
D
ia
s
to
lic
b
lo
o
d
p
re
s
s
u
re
(m
m
H
g
)
2
5
0
m
g
re
s
v
e
ra
tr
o
l
7
5
·6
5
1
·6
6
2
·5
7
0
·9
0
4
·1
7
0
·9
6
T
r
3
·6
8
0
·0
4
5
*
2
5
0
m
g
re
s
v
e
ra
tr
o
l
w
it
h
2
0
m
g
p
ip
e
ri
n
e
7
5
·0
9
1
·6
2
4
·8
3
1
·3
8
4
·7
0
1
·6
5
T
i
0
·6
2
8
0
·4
3
7
P
la
c
e
b
o
7
6
·9
1
2
·4
8
2
0
·1
7
2
·0
8
0
·6
5
1
·7
7
T
r
£
T
i
0
·2
5
8
0
·7
2
4
P
u
ls
e
ra
te
(b
p
m
)
2
5
0
m
g
re
s
v
e
ra
tr
o
l
6
8
·4
3
2
·4
8
2
0
·8
3
1
·0
7
2
2
·2
6
1
·5
1
T
r
1
·7
7
0
·1
9
2
2
5
0
m
g
re
s
v
e
ra
tr
o
l
w
it
h
2
0
m
g
p
ip
e
ri
n
e
6
7
·9
1
2
·1
4
0
·3
5
1
·8
7
2
3
·7
4
3
·7
8
T
i
3
·3
8
0
·0
8
0
t
P
la
c
e
b
o
7
0
·8
7
2
·2
9
2
3
·7
8
1
·6
3
2
6
·8
7
1
·6
3
T
r
£
T
i
0
·3
6
8
0
·5
8
4
P
D
,
p
o
s
t-
d
o
s
e
;
T
r,
tr
e
a
tm
e
n
t;
T
i,
ti
m
e
;
b
p
m
,
b
e
a
ts
p
e
r
m
in
.;
t,
tr
e
n
d
.
T
h
e
re
w
e
re
s
ig
n
ifi
c
a
n
t
m
a
in
e
ff
e
c
ts
fo
r
T
r
a
n
d
T
i:
*
P
,
0
·0
5
,
**
P
,
0
·0
1
.
†
B
a
s
e
lin
e
,
im
m
e
d
ia
te
ly
b
e
fo
re
tr
e
a
tm
e
n
t;
P
D
1
,
4
0
m
in
p
o
s
t-
d
o
s
e
a
n
d
im
m
e
d
ia
te
ly
b
e
fo
re
p
o
s
t-
d
o
s
e
ta
s
k
s
;
P
D
2
,
9
5
m
in
p
o
s
t-
d
o
s
e
a
n
d
im
m
e
d
ia
te
ly
a
ft
e
r
p
o
s
t-
d
o
s
e
ta
s
k
s
.
E. L. Wightman et al.210
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
D
ow
nloaded from
 https://w
w
w
.cam
bridge.org/core . U
niversity of N
ottingham
, on 03 A
ug 2020 at 13:25:59 , subject to the C
am
bridge C
ore term
s of use, available at https://w
w
w
.cam
bridge.org/core/term
s . https://doi.org/10.1017/S0007114514000737
and while the oxygenation effects in the above-mentioned
study in rodents were observed following chronic consump-
tion, these mechanisms would explain the VO2 effects
observed in the present study, represented by deoxy-Hb.
Interestingly, in light of the significant CBF effects occurring
only with the resveratrol/piperine combination, no significant
differences were observed in the plasma concentrations of
resveratrol between the treatments. In both treatment
conditions, resveratrol metabolites were present in the plasma
across the post-dose cognitive task period and the parent
compound was unquantifiable at all time points. However, con-
trary to the hypothesis of piperine-induced bioenhancement,
the pattern of effects observed in the present study actually
suggests inhibition rather than enhancement of plasma con-
centrations; for example, the Cmax of total metabolites after
treatment with 250mg resveratrol was 9·98mM compared with
4·82mM in the piperine co-supplemented condition. Piperine
also appeared to be inhibiting the transit of resveratrol, evi-
denced by the Tmax of metabolites in the 250mg resveratrol
condition occurring at the 90min sample time point compared
with the 120min time point in the co-supplemented condition
and the observation of metabolite concentrations reducing at
the 120min time point in the 250mg resveratrol condition
and not in the co-supplemented condition. Nevertheless, this
pattern of effects exhibited no significant differences between
the treatment groups, which suggests two possibilities: either
piperine can exert CBF effects independently of resveratrol
or, alternatively, it potentiates the effects of resveratrol observed
previously on CBF.
Taking the first of these possibilities into account, it is
notable that there is only one study(33) that suggests that
piperine is capable of interacting with NO and that this is
the inducible NO synthase isoform that is stimulated in
response to immunological stimuli(34) and is not associated
with cerebral vasorelaxation and increased blood flow. No
data exist to suggest that piperine is capable of affecting
oxygenation or indeed any other factor relevant to the present
study, and this precluded the need for a piperine-only treat-
ment condition in the study. The exception here is a small
amount of literature in rats that suggests that chronic (up to
4 weeks) piperine supplementation might improve aspects
of performance, although this appears to be mostly related
to mood augmentation rather than to enhanced cognition
per se (35–37). Nevertheless, future studies investigating the
efficacy of piperine alone on these parameters, in human
subjects, to clarify this issue are warranted.
In light of a lack of evidence to suggest that piperine
has any influence on parameters relevant to CBF, and in the
face of no significant modulation of CBF being observed in
the resveratrol condition alone (a finding mirrored in the
study of Kennedy et al.(10) with the same dose), it seems
more likely that piperine increases the bioefficacy of resvera-
trol by potentiating its vasorelaxatory properties. In support of
this, resveratrol is a well-validated vasorelaxatory mediator(7)
and, at a higher dose (500 mg), can increase CBF in healthy
human subjects(10).
Of the potential mechanisms to explain the efficacy-
enhancing effects of piperine, one is that piperine is able to
enhance the activity of resveratrol, the neuronal vasculature,
and/or some other factor relevant to CBF through its thermo-
genic properties. As evidence of the heat-proffering properties
of piperine, specifically in neural tissue, Reanmongkol et al.(38)
reported on the ability of piperine to stimulate the activity of
ATPase (but inhibition of oxidative phoshorylation), which
produces heat as a by-product(39). Thermogenic increases in
tissue activity have previously been proposed as an expla-
nation for piperine-mediated increases in plasma b-carotene
concentrations in human subjects(13) via an increase in the
absorption rate of the intestinal epithelium and, as a mechan-
ism, could exist without piperine inducing an overall increase
in the bioavailability of resveratrol: a phenomenon observed
previously(11–14), but not replicated in the present study.
In terms of behavioural effects, the results of the present
study are in line with previous findings, i.e. a lack of any
effect of a 250 mg dose of resveratrol with regard to cognitive
task performance(10). One of the primary reasons for using
piperine in the present study was to ascertain whether this
well-established bioenhancer of polyphenols also induces
the enhancement of resveratrol’s bioefficacy, especially in
terms of cognitive function due to the null effects reported
previously. However, while the increase in CBF during task
performance was potentiated by piperine, the pattern was lar-
gely the same as that observed following the administration of
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Fig. 3. Plasma bioavailability of resveratrol metabolites following (a) the
administration of 250mg trans-resveratrol alone and (b) the administration of
250mg trans-resveratrol with 20 mg piperine in healthy, young human subjects.
Values are means (n 6), with their standard errors represented by vertical bars.
X, Concentration of resveratrol 3-O-sulphate; W, combined concentrations of
resveratrol 40-O-glucuronide and resveratrol 3-O-glucuronide.
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a larger dose of resveratrol (500 mg in Kennedy et al.(10)),
where cognitive effects were also lacking. Therefore, it
would appear that acute increases in CBF are not sufficient,
in themselves, to alter cognitive function in the young, healthy
cohorts examined in the present study and previously. How-
ever, it may be the case that longer-term supplementation
is required or indeed that the effects might translate into
cognitive benefits in populations exhibiting age- or pathol-
ogy-related decrements in CBF and cognitive function.
In conclusion, this is the first study to report that
co-supplementation of piperine with resveratrol enhances the
bioefficacy of resveratrol with regard to CBF effects in healthy
human subjects, but not cognitive performance, and does this
without altering the overall bioavailability of resveratrol in vivo.
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